10-Q: Altria Q2 Earnings Hit by NJOY Impairment, Cigarette Declines

Altria Group reports a significant drop in Q2 net earnings and EPS due to a goodwill impairment charge related to its e-vapor unit and the absence of a prior year gain, despite growth in adjusted metrics.

Summary

• Net earnings for the six months ended June 30, 2025, decreased by 41.8% to $3,455 million, down from $5,932 million in the prior year, primarily due to a $2.7 billion gain on the sale of IQOS System commercialization rights in 2024 and a goodwill impairment in 2025.
• Diluted earnings per share (EPS) decreased by 40.2% to $2.04 for the six months ended June 30, 2025, compared to $3.41 in the same period last year.
• Adjusted net earnings increased by 4.3% to $4,522 million, and adjusted diluted EPS rose by 7.2% to $2.67 for the six months ended June 30, 2025, reflecting underlying operational improvements.
• The smokeable products segment saw net revenues decrease by 4.1% and cigarette shipment volume decline by 11.9% for the six months, driven by industry decline, retail share losses, and calendar differences.
• Marlboro's retail share of the total cigarette category decreased by 1.0 percentage point to 41.0% for the six months ended June 30, 2025.
• The oral tobacco products segment's net revenues increased by 3.3% for the six months, with on! oral nicotine pouch shipment volume growing by 22.7%.
• The U.S. nicotine pouch category expanded to 50.6% of the U.S. oral tobacco category, an increase of 9.4 percentage points year-over-year for the six months.
• An $873 million non-cash goodwill impairment charge was recorded in the first quarter of 2025 for the e-vapor reporting unit, primarily due to lower projected volume and revenue following the NJOY ACE U.S. market removal.
• The U.S. International Trade Commission (ITC) issued an exclusion order and cease-and-desist orders prohibiting the importation and sale of NJOY ACE in the United States, effective March 31, 2025.
• Altria authorized a new $1.0 billion share repurchase program in January 2025, with $400 million remaining at June 30, 2025.
• The company's debt-to-Consolidated EBITDA ratio was 2.0 for the twelve months ended June 30, 2025.
• PM USA and Middleton implemented multiple list price increases across their cigarette and cigar brands in 2024 and 2025.
• USSTC and Helix also increased list prices for their moist smokeless tobacco and on! brands in 2024 and 2025.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the significant decline in reported net earnings and EPS, primarily driven by a large goodwill impairment and the absence of a prior-year gain. While adjusted metrics show growth and the oral tobacco segment performs well, the core smokeable products business continues to face substantial volume declines and market share pressure, exacerbated by regulatory challenges and illicit market competition. The ongoing litigation and regulatory uncertainties, particularly regarding NJOY ACE, add to the negative outlook, despite some positive credit rating news.

Positives

• Adjusted net earnings increased by 4.3% to $4,522 million for the six months ended June 30, 2025, indicating underlying operational strength.
• Adjusted diluted EPS grew by 7.2% to $2.67 for the six months ended June 30, 2025, reflecting efficient capital management and share repurchases.
• Net cash provided by operating activities increased to $2,925 million for the six months ended June 30, 2025, up from $2,802 million in the prior year, driven by lower payments for State Settlement Agreements, litigation, excise taxes, and income taxes.
• The oral tobacco products segment demonstrated revenue growth of 3.3% for the six months, with strong performance from on! oral nicotine pouches, which saw shipment volume increase by 22.7%.
• The U.S. nicotine pouch category continues to grow, reaching 50.6% of the U.S. oral tobacco category for the six months, indicating successful transition efforts.
• PM USA and Middleton successfully implemented multiple pricing actions across their smokeable products, contributing to higher OCI despite volume declines.
• USSTC and Helix also implemented pricing actions for their oral tobacco products, supporting revenue growth in the segment.
• The company extended its $3.0 billion senior unsecured 5-year revolving credit agreement from October 24, 2028, to October 24, 2029, enhancing liquidity flexibility.
• S&P upgraded Altria's long-term debt credit rating to BBB+ from BBB and changed the outlook to Stable from Positive on May 14, 2025, reflecting improved creditworthiness.

Negatives

• Reported net earnings decreased significantly by 41.8% to $3,455 million for the six months ended June 30, 2025, primarily due to the absence of a $2.7 billion gain from the IQOS System commercialization rights sale in 2024 and a goodwill impairment in 2025.
• Reported diluted EPS declined by 40.2% to $2.04 for the six months ended June 30, 2025.
• A non-cash goodwill impairment charge of $873 million was recorded for the e-vapor reporting unit in Q1 2025, stemming from the ITC exclusion order on NJOY ACE.
• The smokeable products segment experienced a 4.1% decrease in net revenues and an 11.9% decline in domestic cigarette shipment volume for the six months, driven by industry contraction and market share losses.
• Marlboro's retail share decreased by 1.0 percentage point to 41.0% for the six months, indicating competitive pressures in the premium cigarette market.
• The overall oral tobacco products segment's reported domestic shipment volume decreased by 2.9% for the six months, with Copenhagen and Skoal volumes declining by 8.6% and 11.6% respectively.
• on!'s share of the nicotine pouch category decreased by 0.9 percentage points to 17.3% for the six months, indicating increased competition within the growing category.
• Discretionary income pressures on adult tobacco consumers, due to inflation and tariffs, have led to increased discount brand share performance in the cigarette category (31.2% in Q2 2025, up 1.9 pp).
• The proliferation of illicit flavored disposable e-vapor products, which are believed to evade regulatory processes, continues to negatively impact the e-vapor category and contribute to declines in domestic cigarette consumption.

Risks

• Inability to anticipate and respond to changes in adult tobacco consumer preferences and purchase behavior, including shifts to lower-priced or innovative products.
• Continued growth of illicit disposable e-vapor products, which negatively impacts domestic cigarette consumption and shipment volume.
• Impact of illicit trade in tobacco products and the sale of products designed to avoid the regulatory framework, reducing consumption and shipment volumes.
• Failure to develop and commercialize innovative products that reduce health risks and appeal to adult tobacco consumers.
• Unfavorable outcomes from litigation proceedings or governmental investigations, including significant monetary and non-monetary remedies and importation bans (e.g., NJOY ACE ITC order).
• Risks associated with significant federal, state, and local government actions, including FDA regulatory actions and inaction, and various private sector actions.
• Regulators and courts may interpret laws, rules, and regulations differently than the company, leading to adverse outcomes.
• Increases in tobacco product-related taxes, which can reduce consumption and shift consumers to lower-priced or illicit products.
• Failure to successfully complete or manage strategic transactions, including acquisitions, dispositions, joint ventures, and investments, or to realize anticipated benefits.
• Significant changes in price, availability, or quality of tobacco, other raw materials, or component parts due to macroeconomic, climate, and geopolitical conditions.
• Reliance on a few significant facilities and a small number of key suppliers, distributors, and service providers, posing risks of extended disruptions.
• Potential for additional non-cash impairments of goodwill and intangible assets, particularly for the e-vapor reporting unit if assumptions regarding market conditions or regulatory outcomes do not materialize.
• Risks associated with the 'Optimize & Accelerate' initiative, including business continuity, internal control over financial reporting, and the ability to recognize expected savings.
• Potential for product recalls, which could harm reputation and financial performance.
• Inability to attract and retain a highly skilled workforce due to decreasing social acceptance of tobacco usage and tobacco control actions.
• Risks related to health epidemics and pandemics, potentially leading to temporary closures and restrictions on businesses and facilities.
• Challenges to tax positions, increases in income tax rates, or other changes to federal or state tax laws.
• Legal and regulatory requirements related to climate change and other environmental sustainability matters, potentially increasing costs or limiting product packaging options.
• Disruption and uncertainty in credit and capital markets, including the risk of losing access to these markets or credit rating downgrades.
• Heightened focus by investors and other stakeholders on corporate responsibility matters, potentially impacting investment and reputation.
• Failure of information systems or cyber-attacks affecting the company or its service providers/suppliers.
• Failure to comply with laws related to personal data protection, privacy, artificial intelligence, and information security.
• The risk that expected benefits from the investment in ABI may not materialize as expected.
• Risks associated with the investment in Cronos, including legal, regulatory, and reputational risks, and the risk that expected benefits may not materialize.

Future Outlook

Altria maintains a progressive dividend goal targeting mid-single digits dividend growth annually through 2028. The company expects to complete its $1.0 billion share repurchase program by December 31, 2025. Management anticipates making additional employer contributions of up to approximately $20 million to pension plans and up to approximately $30 million to postretirement plans in 2025. The 'Optimize & Accelerate' initiative, designed to modernize ways of working, is expected to have its design and detailed plans substantially complete in early 2026, with estimated total pre-tax charges of approximately $125 million. The company is monitoring the evolving business, legal, and regulatory challenges, including potential impacts from FDA product standards (e.g., nicotine levels in combustibles, menthol/flavor bans), and ongoing litigation, which could materially affect future results. The rulemaking process for the proposed nicotine product standard is expected to take multiple years to complete. The company does not expect the recently signed One Big Beautiful Bill Act (OBBB) to have a material impact on its consolidated financial statements.

Management Comments

• We are 'Moving Beyond Smoking' by responsibly transitioning adult smokers to a smoke-free future, competing vigorously for existing smoke-free adult nicotine consumers, and exploring new growth opportunities.
• The 'Optimize & Accelerate' initiative is designed to modernize our ways of working, increasing our organization's speed, efficiency, and effectiveness by centralizing work, outsourcing certain transactional tasks, and streamlining, automating, and standardizing processes.
• We believe our cash and cash equivalents balance, along with our future cash flows from operations, capacity for borrowings under our Credit Agreement, and access to credit and capital markets, provide sufficient liquidity to meet the needs of our business operations and to satisfy our projected cash requirements for the foreseeable future, including the next 12 months.
• We believe, and have been so advised by counsel handling the respective cases, that we have valid defenses to the litigation pending against us, as well as valid bases for appeal of adverse verdicts. We have defended, and will continue to defend, vigorously against litigation challenges.
• We support legislation to convert ad valorem taxes on MST to a weight-based methodology because, unlike the ad valorem tax, a weight-based tax subjects cans of equal weight to the same tax.
• We support and advocate for raising the minimum legal age to purchase all tobacco products to 21 at the federal and state levels.

Industry Context

The U.S. tobacco industry continues to face significant headwinds from declining combustible cigarette consumption, driven by evolving adult tobacco consumer preferences, discretionary income pressures (inflation, tariffs), and the proliferation of illicit flavored disposable e-vapor products. The discount segment of the cigarette category is growing, reaching 31.2% share in Q2 2025, indicating a shift in consumer purchasing behavior towards lower-priced options. Conversely, the smoke-free category, particularly oral nicotine pouches, is experiencing robust growth, with the U.S. nicotine pouch category now representing 52.0% of the total U.S. oral tobacco category. However, this growth is challenged by insufficient FDA enforcement against unauthorized products, creating an uneven playing field. Regulatory uncertainty, including potential FDA product standards (nicotine reduction, flavor bans), continues to shape the competitive landscape and poses long-term risks to traditional tobacco products while also impacting the development and market authorization of innovative products. Geopolitical and macroeconomic conditions are also affecting supply chains and raw material costs across the industry.

Comparison to Industry Standards

• Altria's domestic cigarette shipment volume decline of 11.9% for the six months ended June 30, 2025, is worse than the estimated total domestic cigarette industry volume decline of 8.5% (adjusted for calendar differences, trade inventory movements, and other factors) for the second quarter of 2025, indicating market share losses beyond the general industry trend.
• Marlboro's retail share of 41.0% for the six months ended June 30, 2025, while still dominant, represents a 1.0 percentage point decrease, suggesting competitive pressure from other brands or categories.
• The U.S. nicotine pouch category's growth to 50.6% of the U.S. oral tobacco category for the six months ended June 30, 2025, demonstrates a significant industry shift towards smoke-free alternatives, aligning with broader global trends seen in companies like Philip Morris International (PMI) with its IQOS products, though Altria's on! brand's share of the nicotine pouch category decreased by 0.9 percentage points to 17.3%, indicating strong competition within this growth segment.
• The increase in the discount share of the cigarette category to 31.2% in Q2 2025 (up 1.9 share points) reflects a broader industry trend of consumers trading down due to economic pressures, a challenge faced by all premium brand manufacturers.

Corporate Governance

Legal Proceedings

• Altria and certain affiliates, including NJOY, are defendants in lawsuits alleging patent infringement based on the sale of NJOY ACE in the United States. The U.S. International Trade Commission (ITC) issued an exclusion order and cease-and-desist orders prohibiting the importation and sale of NJOY ACE in the United States, effective March 31, 2025. Altria has appealed this determination.
• NJOY filed a complaint against JUUL in the U.S. District Court for the District of Delaware asserting patent infringement claims, which is currently stayed. NJOY also filed a related action with the ITC, which concluded that JUUL products do not infringe NJOY's patents. Altria appealed this ITC determination but voluntarily dismissed the appeal in July 2025 and moved to lift the stay on the District Court lawsuit.
• Ongoing disputes under the State Settlement Agreements regarding Non-Participating Manufacturer (NPM) Adjustments, with arbitrations for 2005-2007 disputes ongoing and PM USA having recorded $35 million for its estimated minimum receipt.
• PM USA settled a dispute with Mississippi over profit adjustment payments for $7 million in Q3 2024. However, a U.S. District Court found PM USA owes $31 million to the State of Texas for a similar tax rate issue, which PM USA has appealed. The State of Minnesota also filed a motion on similar issues, with the court finding in favor of Minnesota, and PM USA intends to appeal.
• The U.S. government's RICO lawsuit against Altria and PM USA continues, with corrective statements remedy ongoing. A $15 million provision was recorded in Q1 2024 for estimated costs of implementing corrective statements on point-of-sale signage.
• The majority of the Multidistrict Litigation lawsuits and consolidated California state court proceedings related to JUUL e-vapor products were settled for $235 million in Q2 2023, with payment made in Q2 2024. A separate settlement for Native American tribes for $20 million was paid in October 2024.
• Seventeen putative class action antitrust lawsuits are pending against Altria and JUUL in the U.S. District Court for the Northern District of California, alleging violations of antitrust laws. A trial is set to commence in May 2026.
• PM USA is a defendant in the Amaral case in Massachusetts, where a jury awarded $4 million in compensatory damages and $25 million in punitive damages against PM USA. Post-trial motions and appeals are pending.
• PM USA is a defendant in the Taylor case in Oregon, where a jury awarded less than $1 million in compensatory damages. Appeals are pending.
• PM USA is a defendant in the Ricapor-Hall case in Hawaii, where a jury awarded $6 million in compensatory damages and $8 million in punitive damages, later reduced to $3 million compensatory and $8 million punitive. Appeals are pending.
• The Woodley case in Massachusetts, where a jury awarded $5 million in compensatory damages against PM USA, was affirmed on appeal, and PM USA paid the $5 million judgment in Q1 2025.
• The Fontaine case in Massachusetts, where a jury awarded $8 million in compensatory damages and $1 billion in punitive damages (reduced to $56 million), is pending appeal to the Massachusetts Supreme Judicial Court.

Related Party Transactions

• Under the terms of a distribution agreement between Altria and Philip Morris International Inc. (PMI), liabilities concerning tobacco products are allocated based on the manufacturer. PMI indemnifies Altria and PM USA for liabilities related to tobacco products manufactured by PMI or contract manufactured for PMI by PM USA, and PM USA indemnifies PMI for liabilities related to tobacco products manufactured by PM USA, excluding contract manufactured products for PMI. PMI has agreed not to seek indemnification for the active IQOS System patent litigation.

Stakeholder Impact

• Shareholders: Experienced a significant decline in reported net earnings and EPS, but adjusted metrics show growth. The new share repurchase program and progressive dividend goal aim to return value. However, ongoing litigation and regulatory risks could impact future returns.
• Employees: The 'Optimize & Accelerate' initiative is designed to modernize ways of working, potentially impacting roles and processes through centralization, outsourcing, and streamlining.
• Customers (Adult Tobacco Consumers): Face discretionary income pressures leading to shifts towards discount brands. The market for e-vapor and oral nicotine pouches is evolving, with new product introductions and regulatory actions affecting product availability and choice.
• Suppliers: Macroeconomic conditions, tariffs, inflation, and geopolitical instability are causing disruptions and increasing costs for raw materials and component parts, potentially impacting supplier relationships and stability.
• Creditors: S&P's upgrade of Altria's long-term debt credit rating to BBB+ with a stable outlook is positive for creditors, indicating improved creditworthiness. The extension of the credit agreement also provides stability.
• Regulatory Authorities: The company is actively engaging with the FDA on regulatory frameworks, including PMTAs and proposed product standards, and is subject to ongoing enforcement actions and investigations.

Next Steps

• Complete the remaining $400 million under the January 2025 share repurchase program by December 31, 2025.
• Continue to engage with the FDA through the rulemaking process regarding the proposed tobacco product standard for maximum nicotine levels in combustible products, with the public comment period closing on September 15, 2025.
• Further develop and finalize detailed plans for additional phases of the 'Optimize & Accelerate' initiative, with design and plans expected to be substantially complete in early 2026.
• Monitor and respond to ongoing litigation, including appeals related to the NJOY ACE ITC exclusion order and the antitrust litigation against Altria and JUUL, with a trial set for May 2026.
• Continue to make employer contributions to pension plans (up to $20 million) and postretirement plans (up to $30 million) in 2025.
• PM USA will appeal the court's decision in the Texas State Settlement Agreement dispute, where it was found to owe $31 million to the State of Texas.
• PM USA intends to appeal the Minnesota state court's finding in favor of the State of Minnesota regarding tax rate issues in the Minnesota State Settlement Agreement.

Key Dates

Recommendation

Altria's Q2 2025 filing presents a mixed picture. While reported net earnings and EPS saw a substantial decline due to a goodwill impairment and the absence of a prior-year gain, the adjusted metrics show positive growth, indicating underlying operational resilience. The company's oral tobacco segment, particularly 'on!' nicotine pouches, continues to perform well and aligns with the 'Moving Beyond Smoking' vision. However, the core combustible cigarette business faces persistent volume declines and market share erosion, exacerbated by economic pressures and the rise of illicit e-vapor products. Significant regulatory and litigation uncertainties, such as the NJOY ACE import ban and ongoing patent disputes, pose material risks. The recent credit rating upgrade is a positive, but the overall environment remains challenging. Given the strong dividend yield and commitment to shareholder returns, but also the significant headwinds and uncertainties in its traditional and innovative product categories, a 'hold' recommendation is appropriate for investors seeking income with an understanding of the inherent industry risks.

Keywords

Altria Group, MO, SEC 10-Q, Quarterly Report, Tobacco Industry, Cigarettes, Marlboro, Oral Tobacco, Moist Smokeless Tobacco, Nicotine Pouches, on!, E-vapor, NJOY, Goodwill Impairment, ITC Exclusion Order, FDA Regulation, Financial Performance, Earnings, EPS, Share Repurchase, Dividends, Litigation, Risk Factors, Capital Markets, Credit Ratings, Anheuser-Busch InBev, Cronos Group